INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Institutua
Iuliu Hațieganu University of Medicine and Pharmacy
Cluj, RumaníaIuliu Hațieganu University of Medicine and Pharmacy-ko ikertzaileekin lankidetzan egindako argitalpenak (7)
2024
-
Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)
Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 10, pp. 1248-1259
2022
-
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121
-
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study
Liver International, Vol. 42, Núm. 8, pp. 1891-1901
2020
2019
-
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
The Lancet, Vol. 394, Núm. 10193, pp. 121-130
-
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
The Lancet, Vol. 394, Núm. 10193, pp. 131-138
2011
-
Usefulness of a centralized system of data collection for the development of an international multicentre registry of spondyloarthritis
Rheumatology, Vol. 50, Núm. 1, pp. 132-136